Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 5
2019 3
2020 11
2021 8
2022 7
2023 7
2024 13
2025 16
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Comprehensive review of chromophobe renal cell carcinoma.
Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Garje R, et al. Crit Rev Oncol Hematol. 2021 Apr;160:103287. doi: 10.1016/j.critrevonc.2021.103287. Epub 2021 Mar 19. Crit Rev Oncol Hematol. 2021. PMID: 33753250 Free article. Review.
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, Fang B, Adra N, Garje R, Michalski JM, Chi K, de Bono J, Fizazi K, Krause B, Sartor O, Tagawa ST, Ghebremariam S, Brackman M, Wong CC, Catafau AM, Benson T, Armstrong AJ, Herrmann K. Kuo PH, et al. Among authors: garje r. Radiology. 2024 Aug;312(2):e233460. doi: 10.1148/radiol.233460. Radiology. 2024. PMID: 39162634 Free PMC article. Clinical Trial.
Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
Garje R, Riaz IB, Naqvi SAA, Rumble RB, Taplin ME, Kungel TM, Herchenhorn D, Zhang T, Beckermann KE, Vapiwala N, Carducci MA, Celano P, Hotte SJ, Basu A, Borno H, Bryce AH, Wang P, Wulff-Burchfield E, Bodei L, Loblaw A, Hamilton RJ, Emamekhoo H, Hope TA, He H, Murad MH, Liu H, Williams JE Jr, Parikh RA. Garje R, et al. J Clin Oncol. 2025 Jul 10;43(20):2311-2334. doi: 10.1200/JCO-25-00007. Epub 2025 May 2. J Clin Oncol. 2025. PMID: 40315400
Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.
Chi KN, Armstrong AJ, Krause BJ, Herrmann K, Rahbar K, de Bono JS, Adra N, Garje R, Michalski JM, Kempel MM, Fizazi K, Morris MJ, Sartor O, Brackman M, DeSilvio M, Wilke C, Holder G, Tagawa ST. Chi KN, et al. Among authors: garje r. Eur Urol. 2024 Apr;85(4):382-391. doi: 10.1016/j.eururo.2023.12.004. Epub 2024 Jan 6. Eur Urol. 2024. PMID: 38185538 Free PMC article. Clinical Trial.
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review.
Naqvi SAA, Anjum MU, Bibi A, Khan MA, Khakwani KZR, He H, Imran M, Kazmi SZ, Raina A, Cobran EK, Bryan Rumble R, Oliver TK, Agarwal N, Zakharia Y, Taplin ME, Sartor O, Singh P, Orme JJ, Childs DS, Parikh RA, Garje R, Murad MH, Bryce AH, Riaz IB. Naqvi SAA, et al. Among authors: garje r. medRxiv [Preprint]. 2025 Apr 16:2025.04.15.25325837. doi: 10.1101/2025.04.15.25325837. medRxiv. 2025. PMID: 40321256 Free PMC article. Preprint.
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Among authors: garje r. Cancer Res Commun. 2024 May 30;4(5):1369-1379. doi: 10.1158/2767-9764.CRC-23-0546. Cancer Res Commun. 2024. PMID: 38709075 Free PMC article.
Dabigatran-related leukocytoclastic vasculitis.
An J, Garje R, Wanat KA, Leone JP. An J, et al. Among authors: garje r. BMJ Case Rep. 2017 Jan 4;2017:bcr2016217423. doi: 10.1136/bcr-2016-217423. BMJ Case Rep. 2017. PMID: 28052946 Free PMC article.
Immunotherapy Advances in Urothelial Carcinoma.
Jain RK, Snyders T, Nandagopal L, Garje R, Zakharia Y, Gupta S. Jain RK, et al. Among authors: garje r. Curr Treat Options Oncol. 2018 Dec 15;19(12):79. doi: 10.1007/s11864-018-0598-x. Curr Treat Options Oncol. 2018. PMID: 30554335 Review.
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes.
Graham LS, Henderson NC, Kellezi O, Hwang C, Barata PC, Bilen MA, Kilari D, Pierro M, Thapa B, Tripathi A, Mo G, Labriola M, Park JJ, Rothstein S, Garje R, Koshkin VS, Patel VG, Dorff T, Armstrong AJ, McKay RR, Alva A, Schweizer MT. Graham LS, et al. Among authors: garje r. JCO Precis Oncol. 2024 Aug;8:e2400014. doi: 10.1200/PO.24.00014. JCO Precis Oncol. 2024. PMID: 39178368 Free PMC article.
67 results